18:22 , May 7, 2019 |  BC Extra  |  Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence acalabrutinib as...
22:27 , Nov 6, 2018 |  BioCentury  |  Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic. In a prospectus...
17:40 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse studies suggest combined promotion of BDNF expression and neurogenesis could help treat AD. In a mouse model of familial AD, the combination of three agents -- a tool compound that...
15:21 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Patient sample and cell culture studies suggest inhibiting BDNF-TrkB signaling could help treat prostate cancer in African-American patients. In prostate fibroblasts isolated from four African-American patients, levels of BDNF were higher than...
22:10 , Sep 6, 2018 |  BC Extra  |  Preclinical News

Dual therapy could treat AD -- if it can cross into clinic

Researchers at Massachusetts General Hospital and colleagues found concurrently inducing neurogenesis and raising neuroprotective brain-derived neurotrophic factor (BDNF) levels could treat Alzheimer's disease, but it's not clear if -- or how -- such strategies could...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus...
16:06 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest a TrkB-agonizing BDNF peptide could help treat demyelination diseases. In a mouse model of CNS demyelination, intracerebroventricular infusion of a previously reported tricyclic BDNF peptide agonist of TrkB (EC 50...
21:27 , Aug 10, 2018 |  BC Extra  |  Company News

Astellas acquires ophthalmic company Quethera

Astellas Pharma Inc. (Tokyo:4503) acquired ophthalmic gene therapy company Quethera Ltd. (Cambridge, U.K.) for up to £85 million ($110.3 million). "This acquisition is a strategic fit as Astellas has prioritized ophthalmology as a new focus...
20:45 , Sep 14, 2017 |  BC Innovations  |  Translation in Brief

Tracking TrkB agonists

It turns out that neurotrophic TrkB agonists used in many publications aren't TrkB agonists after all, according to a recent Science Signaling paper from Columbia University and the Broad Institute of MIT and Harvard ....
16:22 , Aug 31, 2017 |  BC Innovations  |  Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience , a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in...